Increasing Safety, Efficacy, and Global Equity with Intranasal Vaccines

BlueWillow Biologics Chief Executive Officer Chad Costley, M.D., discusses the historical development of mucosal and intranasal vaccines and their advantages over intramuscular delivery.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: